ContributorsPublishersAdvertisers

Oral Antiviral Drug Cuts COVID-19 Hospitalization in Half

Cancer Health
Cancer Health
 2021-10-02
Cover picture for the article

Molnupirvair, an experimental oral antiviral, reduced the chances of hospitalization or death by about 50% among people with mild to moderate COVID-19 in an international trial, according to an announcement from Merck and Ridgeback Biotherapeutics. The study was halted early and the companies plan to request Food and Drug Administration (FDA)...

www.cancerhealth.com

Comments / 0

Comments / 0